Evidence map›Paper›PMID 39901598›Full record

SynthesisJournal of neurochemistry2025

Challenges and Opportunities in Exploring Non-Motor Symptoms in 6-Hydroxydopamine Models of Parkinson's Disease: A Systematic Review.

Mateus Prates-Rodrigues, Beatriz Lage Araújo Schweizer, Clara de Paula Gomes, Ângela Maria Ribeiro, Fernando E Padovan-Neto, Debora Masini, Cleiton Lopes-Aguiar

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mateus Prates-RodriguesDepartamento de Fisiologia e Biofísica, Laboratório de Neurociências Comportamental e Molecular (LANEC), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0009-0005-0508-5298
Beatriz Lage Araújo SchweizerDepartamento de Fisiologia e Biofísica, Laboratório de Neurociências Comportamental e Molecular (LANEC), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0009-0007-0511-4495
Clara de Paula GomesDepartamento de Fisiologia e Biofísica, Laboratório de Neurociências Comportamental e Molecular (LANEC), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-7286-7063
Ângela Maria RibeiroDepartamento de Fisiologia e Biofísica, Laboratório de Neurociências Comportamental e Molecular (LANEC), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Fernando E Padovan-NetoDepartment of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.ORCID 0000-0002-5529-3168
Debora MasiniDepartment of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.ORCID 0000-0003-1467-2388
Cleiton Lopes-AguiarDepartamento de Fisiologia e Biofísica, Laboratório de Neurociências Comportamental e Molecular (LANEC), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0001-9310-6338

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00246-21Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02074-24Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02859-23Fundação de Amparo à Pesquisa do Estado de Minas Gerais BPD-00738-22Fundação de Amparo à Pesquisa do Estado de Minas Gerais RED-00187-22International Society for Neurochemistry (ISN), Career Development Grant (CDG)
6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of midbrain dopaminergic neurons, leading to motor symptoms such as tremors, rigidity, and bradykinesia. Non-motor symptoms, including depression, hyposmia, and sleep disturbances, often emerge in the early stages of PD, but their mechanisms remain poorly understood. The 6-hydroxydopamine (6-OHDA) rodent model is a well-established tool for preclinical research, replicating key motor and non-motor symptoms of PD. In this review, we systematically analyzed 135 studies that used 6-OHDA rodent models of PD to investigate non-motor symptoms. The review process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our analysis highlights the growing use of 6-OHDA PD models for experimental research of non-motor symptoms. It also reveals significant variability in methodologies, including choices of brain target, toxin dosage, lesion verification strategies, and behavioral assessment reporting. Factors that hinder reproducibility and comparability of findings across studies. We highlight the need for standardization in 6-OHDA-based models with particular emphasis on consistent evaluation of lesion extent and reporting of the co-occurrence of non-motor symptoms. By fostering methodological coherence, this framework aims to enhance the reproducibility, reliability, and translational value of 6-OHDA models in PD non-motor symptom research.

Indexed as

OxidopamineParkinson DiseaseAnimalsDisease Models, AnimalHumansOxidopamine6‐OHDAanxietydepressionParkinson's diseasepreclinicalrodentsleepsocial interactionstriatumsubstantia nigra

Identifiers

PMID39901598
PMCPMC11791392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.